已收录 273616 条政策
 政策提纲
  • 暂无提纲
Histone deacetylase inhibitors in multiple myeloma
[摘要] Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed.Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 血液学
[关键词] quantum well;conduction-band-electron;circularly polarized photoluminescence;phase-space filling. [时效性] 
   浏览次数:14      统一登录查看全文      激活码登录查看全文